Company news
Fate Therapeutics, Inc. news in 2020
Fate Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.
Fate Therapeutics Presents Patient Case Study Demonstrating Clinical Activity of FT596 in Refractory Diffuse Large B-cell Lymphoma
December 5, 2020
Fate Therapeutics Reports Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma
December 3, 2020
Fate Therapeutics to Host Virtual Event at the 2020 ASH Annual Meeting
November 29, 2020
Fate Therapeutics Announces Participation in Upcoming Investor Conferences
November 11, 2020
Fate Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Operational Progress
November 4, 2020
Fate Therapeutics Announces Twelve Presentations at the 2020 ASH Annual Meeting
November 4, 2020
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2020 Financial Results
November 1, 2020
Fate Therapeutics Announces Presentations at the 2020 Society for Immunotherapy of Cancer Annual Meeting
October 14, 2020
Fate Therapeutics to Present at Jefferies Cell Therapy Virtual Summit
September 29, 2020
Fate Therapeutics Announces September Investor Events
September 3, 2020
Fate Therapeutics Appoints Edward Dulac as Chief Financial Officer
August 18, 2020
Fate Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Operational Progress
August 4, 2020
Fate Therapeutics to Present at the Wedbush PacGrow Healthcare Virtual Conference
August 3, 2020
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2020 Financial Results
July 28, 2020
Fate Therapeutics Announces Exclusive License Agreement with Baylor College of Medicine for Rejection-resistant iPSC-derived Cellular Therapies
July 13, 2020
Fate Therapeutics Announces FDA Clearance of IND Application for First-ever iPSC-derived CAR T-Cell Therapy
July 8, 2020
Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 10, 2020
Fate Therapeutics Announces Pricing of Public Offering of Common Stock
June 8, 2020
Fate Therapeutics Announces Proposed Public Offering of Common Stock
June 7, 2020
Fate Therapeutics Announces FDA Clearance of IND Application for FT538, First CRISPR-edited, iPSC-derived Cell Therapy
May 19, 2020
Fate Therapeutics Reports First Quarter 2020 Financial Results and Highlights Operational Progress
May 10, 2020
Fate Therapeutics Announces Changes to its Board of Directors
May 4, 2020
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2020 Financial Results
May 3, 2020
Fate Therapeutics Announces Preclinical Data Presentation of Novel CAR MICA/B Cell-based Cancer Immunotherapy Program at the 2020 ASGCT Annual Meeting
April 27, 2020
Fate Therapeutics Announces Worldwide Collaboration with Janssen for Novel iPSC-derived Cell-based Cancer Immunotherapies
April 1, 2020
Fate Therapeutics Announces First Patient Treated in First-in-human Clinical Trial of FT596 and Provides Corporate Update
April 1, 2020
Fate Therapeutics Reports Fourth Quarter 2019 Financial Results and Operational Progress with 2020 Outlook
March 1, 2020
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2019 Financial Results
February 25, 2020
Fate Therapeutics Announces Expansion of FT516 Clinical Investigation and Publication of Preclinical Data in the Journal Blood
January 12, 2020